Back to Journals » Clinical Ophthalmology » Volume 9

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population: letter to the editor

Authors Stewart M

Received 4 June 2015

Accepted for publication 4 June 2015

Published 8 September 2015 Volume 2015:9 Pages 1651—1653

DOI https://doi.org/10.2147/OPTH.S89831

Checked for plagiarism Yes

Editor who approved publication: Dr Scott Fraser


Michael W Stewart

Department of Ophthalmology, Mayo Clinic Florida, Jacksonville, FL, USA
 
In their recently published manuscript entitled “Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population” Basheer et al1 reported on the prospectively acquired results of 123 eyes (106 patients) treated for 2 years with ranibizumab as needed. Visual acuity (VA) outcomes from this series were summarized by the following statement: “Although our results, and those from other clinical settings, do not quite match the degree of vision preservation and gain as the large clinical trials, they are not dramatically dissimilar”.1 Unfortunately, the authors provide no statistical analysis to support this statement.

View original paper by Basheer and colleagues.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]